What changed from existing technology?
This study compares the cost-effectiveness of a new gene therapy for severe and moderately severe hemophilia B with a standard treatment in Sweden, looking at long-term health and financial outcomes.
This is the first study to evaluate the long-term cost-effectiveness of a one-time gene therapy for haemophilia B compared to traditional prophylactic treatments in a real-world healthcare setting.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 3
Cost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult pati
Title ↗mpared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in Sweden. Introduction Etranacogene dezaparvo
Title ↗OpenAlex author affiliations: PAREXEL International (United Kingdom), PAREXEL International (United States)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This analysis could inform healthcare policy decisions regarding the adoption of gene therapy for haemophilia B in Sweden, considering long-term cost and health outcomes.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchCost-effectiveness of etranacogene dezaparvovec compared to eftrenonacog alfa for the treatment of adult patients with severe and moderately severe haemophilia B in SwedenJournal of Medical Economics · Published 2026-10-04 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.